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Abstract 
Purpose: To investigate the anti-depressant-like activity of curculigoside from Curculigo orchioides 
Gaertn and its underlying mechanism(s). 
Methods: Antidepressant-like activity was determined in mice through forced swimming test (FST), tail 
suspending test (TST), and open field test (OFT). Mechanism of action was investigated by measuring 
levels of dopamine (DA), norepinephrine (NE), and 5-hydroxytryptamine (5-HT) in chronic mild stress 
(CMS) rats using high-performance liquid chromatography-electron capture detector (HPLC-ECD). 
Western blotting was used to investigate the effect of curculigoside on the expression of brain-derived 
neurotrophic factor (BDNF) protein in rats.  
Results: In FST and TST, treatment of mice with curculigoside (10, 20, 40 mg/kg, p.o.) significantly 
reduced immobility time, which was, however, unaffected by locomotor activity when assessed in the 
OFT. The treatment led to significant increases in DA, NE and 5-HT, and up-regulation of BDNF protein 
expression in the hippocampus of the CMS rats. 
Conclusion: These results demonstrate that curculigoside exerts significant anti-depressant-like activity 
on mice, the mechanism of which involves increase in the levels of DA, NE, 5-HT, and up-regulation of 
BDNF expression. Thus, curculigoside can be considered a potential drug candidate for the treatment of 
depressive disorders. 
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Depression, a common mental disorder, is a 
leading cause of disability all over the world [1]. It 
may be long-lasting or recurrent, and it 
substantially affects the thoughts, behavior, 
feelings and sense of well-being of affected 
individuals. In recent years, there has been an 
increase in depression-associated morbidity and 
mortality in the world. According to a World 
Health Organization (WHO) report, there are 
about 350 million people with depression [2]. By 
2030, researchers predict that depression will be 
one of the three leading causes of illness and a 
major contributor to the overall global burden of 
disease [2]. Mild depression may not require any 
professional treatment, but prolonged or severe 
depression often requires medication and 
professional management. Although there have 
been some improvement in the pharmacotherapy 
of depression, approximately 30–40 percent of 
depressive patients are still unable to achieve full 
remission [3]. Therefore, there is an urgent need 
for development of effective and alternative anti-
depressant drugs with low side-effects. 
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Curculigoside, a phenolic glycoside, is extracted 
from the roots of Curculigo orchioides Gaertn, 
and it is the major bioactive compound in this 
herbal plant [4]. Curculigo orchioides Gaertn 
belongs to the family Amaryllidacea and is often 
used in traditional Chinese medicine for treating 
impotence, limb limpness, diarrhea and arthritis 
[5]. In India, C. orchioides is used as a potent 
immuno-modulator and aphrodisiac in Ayurvedic 
medical system [5]. 
 
Curculigoside has been reported to exhibit 
various pharmacological properties. These 
include anti-oxidant, anti-osteoporotic and neuro-
protective activities [6-9]. In addition, a study has 
shown that curculigoside improves cognitive 
function (learning and memory) in aged rats by 
inhibition of cerebral acetyl cholinesterase 
(AchE) activity and down-regulation of 
expression of β-site APP-cleaving enzyme 1 
(BACE1)  in the hippocampus [4]. 
 
To the best of our knowledge, only a few 
publications have reported the antidepressant 
properties of curculigoside isolated from C. 
orchioides. Moreover, not much is known about 
the mechanism by which it exerts its 
pharmacological action. The present study was 
carried out to investigate the antidepressant-like 







Roots of C. orchioides were purchased from 
Tong-ren-tang Pharmaceutical Group (Taiyuan, 
China) in 2014 and identified by a taxonomist at 
the Department of Traditional Chinese Medicine 
in Shanxi Provincial People’s Hospital (No. 29 
Taiyuan Twin Towers Temple Street, Taiyuan, 
China). A voucher specimen of C. orchioides 





Methanol (MeOH) (analytical reagent, AR), ethyl 
acetate (AR), n-butanol (AR) and petroleum 
ether (AR) were purchased from Sinopharm 
Chemical Reagent Co., Ltd. (Shanghai, China); 
silica gel for column chromatography (100 – 200 
and 200 – 300 mesh) was obtained from 
Qingdao Haiyang Chemical Co., Ltd. (Qingdao, 
China); Sephadex LH-20 was supplied by GE 
Healthcare Co. (Skokie, IL, USA); imipramine 
was purchased from Aladdin Reagent Co. Ltd. 
(Shanghai, China), BCA protein assay reagent 
was purchased from Beyotime (Haimen, China); 
goat-anti-rabbit/rat horseradish- peroxidase- 
conjugated (HRP) secondary antibody was a 
product of Beyotime Biotechnology (Haimen, 
China). Others include brain-derived 
neurotrophic factor (BNDF) antibody (Santa Cruz 
Biotechnology CA, USA) and β-actin antibody 
(Abcam Biotechnology, Cambridge, MA, USA). 
All other regents used in the present 
investigation were of AR grade. 
 
Preparation of pure curculigoside 
 
The dried roots of C. orchioides were powdered 
and extracted by refluxing three times with 75 % 
aqueous ethanol, each for 90 min. The filtrates 
were concentrated by rotary evaporation at 60 °C 
in vacuum. Subsequently, the extract was re-
extracted with ethyl acetate, and then the ethyl 
acetate extract (ACE) was fractionated by silica-
gel column chromatography. Elution was carried 
out with graded volume ratios of petroleum ether 
and acetone (20 : 1, 15 : 1, 10 : 1, 5 : 1, 1 : 1 and 
1 : 2) to obtain a series sub-fractions (I-IV) based 
on thin-layer chromatography (TLC) analysis. 
Then, fraction III was subjected to Sephadex LH-
20 chromatography and eluted with MeOH to 




The animals were purchased from the Laboratory 
Animal Center of Shanxi Institute of Chinese 
Medicine (Shanxi, China). Experimental groups 
consisted of Institute of Cancer Research (ICR) 
mice (male, 20 ± 2 g) or Sprague-Dawley (SD) 
rats (220 ± 20 g). Animals were housed at 25 °C 
under a 12 h light/12 h dark cycle, with free 
access to standard laboratory chow and water. 
Each animal was used only once in the 
experiment. The experimental protocols were 
approved by the Animal Care and Use 
Committee of Shanxi Provincial People’s 
Hospital (approval no. Animal-2015-1017#). The 
animals were handled according to standard 




The anti-depressive effect of curculigoside was 
studied in mice using forced swimming test 
(FST), tail suspending test (TST), and open field 
test (OFT). The levels of dopamine (DA), 
norepinephrine (NE), and 5-hydroxytryptamine 
(5-HT) in the brain of chronic mild stress (CMS) 
rats were measured by HPLC-ECD. 
Furthermore, the effects of curculigoside on the 
expression of brain-derived neurotrophic factor 
(BDNF) protein in the hippocampus of the CMS 
rats were determined by western blotting.  
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In these experiments, 50 mice or rats were 
randomly divided into 5 groups (n = 10), 
including one control, one positive control and 
three curculigoside testing groups. Based on 
previous investigations [4], the doses of the 
curculigoside were 10, 20 and 40 mg/kg. 
Imipramine (for positive control group) was 
administered by intraperitoneal (i.p.) injection, 
while curculigoside was administered orally. The 
control group was treated with an equivalent 
volume of the vehicle (DMSO) in which 
curculigoside was suspended. 
 
Forced swimming test (FST) 
 
The forced swimming test (FST) was carried out 
on mice as reported previously [11]. Mice were 
pre-treated with curculigoside (10, 20, 40 mg/kg, 
p.o.) 1 h before the FST, and imipramine (15 
mg/kg, i.p.) was administered 30 min before the 
test. The mice were dropped individually into 
glass cylinders (14 × 14 × 25 cm) containing 
water 20 cm deep at 25 ± 2 °C. Then mice were 
allowed to swim for 6 min in the water and their 
immobility durations were recorded during the 
last 4 min. 
 
Tail suspension test (TST) 
 
Total duration of immobility induced by tail 
suspension was determined in mice as described 
previously [11]. Curculigoside (10, 20, 40 mg/kg, 
p.o.) was administered 1 h before TST, while 
imipramine (15 mg/kg, i.p.) was given 30 min 
before the test. Mice were individually suspended 
50 cm above the floor in clear black Plexiglass 
boxes (30 × 30 × 45 cm) by adhesive tape 
placed approximately 1 cm from the tip of the tail. 
When the mice hung passively and completely 
motionless, they were considered immobile. 
Immobility time was recorded during a 6-min test. 
 
Evaluation of locomotor activity 
 
This open field test (OFT) was performed to 
eliminate possible influence of drug treatments 
on locomotor activity. The test was carried out in 
clear black Plexiglas boxes (41 × 41 × 41 cm) 
equipped with the video-based Ethovision 
System (Noldus, Wageningen, The Netherlands). 
Illumination was identical to that used for FST 
and TST. Mice were pre-treated with 
curculigoside (10, 20, 40 mg/kg, p.o.) 1 h prior to 
the OFT, or imipramine (15 mg/kg, i.p.) 30 min 
before the test. In the experiment, mice were 
individually and gently placed in the center of the 
open-field apparatus and locomotor activity was 
measured by video for 5 min. This measurement 
was taken from 9 o’clock in the morning. The 
total ambulatory distance and the frequency of 
rearing were recorded as the horizontal 
locomotor activity. 
 
Preparation of chronic mild stress (CMS) 
model rats 
 
Chronic mild stress (CMS) model was 
established in rats in line with previous methods 
[4,12] but with some modifications. The rats were 
exposed to the following ten stressors for 28 
consecutive days: (1) overnight illumination; (2) 
deprivation of food or water (24 h); (3) restricted 
access to food (24 h); (4) clip on the tail for 1 
min; (5) forced swimming (30 min, water 
temperature 25 °C); (6) forced swimming (5 min, 
water temperature 10 °C); (7) soiled cage (200 
ml water spilled onto 100 g sawdust bedding); (8) 
wet bedding for 24 h; (9) white noise (approx. 
110 dB); and (10) cage tilt (45°, 24 h). The rats 
were stimulated with one stressor every day. 
Each stressor was used two or three times, but 
the same stressor was not repeated in four days. 
Rats in the control group were housed without 
any stressors in a separate room, with free 
access to food and water. The rats were treated 
with curculigoside (10, 20, 40 mg/kg, p.o.) or 
imipramine (15 mg/kg, i.p.) once a day. The 
control group was treated with an equivalent 
volume of DMSO once a day at the same time. 
 
Determination of DA, NE, and 5-HT in the 
brain of CMS rats 
 
After 4 weeks of stress procedure, all rats were 
sacrificed by cervical dislocation. The brain of 
each rat was removed and the hippocampus 
tissue was isolated, and weighed. DA, NE, and 
5-HT were measured by high performance liquid 
chromatography-electron capture detector 
(HPLC-ECD). 
 
Assessment of brain-derived neurotrophic 
factor (BNDF) expression by western blotting 
 
The hippocampus samples were homogenized, 
and total proteins were extracted by western blot 
and IP cell lysis buffer kit. Protein content was 
quantified with BCA Protein Assay Reagent. 
Then equal amounts of protein (40 μg) were 
separated by sodium dodecyl sulfate-
polyacrylamide electrophoresis (SDS-PAGE) and 
transferred to polyvinylidene difluoride (PVDF). 
Subsequently, the membrane was probed with 
anti-BDNF rabbit polyclonal IgG (1:200) and anti-
β-actin rabbit polyclonal IgG (1: 200) at 4 °C for 
12 h, followed by incubation with horseradish-
peroxidase-conjugated goat anti-rabbit IgG. 
Finally, the immune-reactive bands were 
visualized with ECL-detecting reagent. 
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All data are presented as mean ± standard 
deviation (SD). Statistical analysis was 
performed via one-way analysis of variance, 
followed by Dunnett’s test using SPSS software 
version 19.0, and differences were considered 




Identification of curculigoside  
 
The structure of the isolated chemical compound 
was identified by 1H-NMR and 13C-NMR as 
curculigoside in line with previous reports [4,13]. 
The spectral data and chemical structure of 
curculigoside are shown in Table 1 and Figure 1 
respectively. 
 
Anti-depression-like effects of curculigoside 
in FST 
 
The effects of curculigoside on total duration of 
immobility induced by FST in mice are shown in 
Fig. 2. Curculigoside (at doses of 10, 20 and 40 
mg/kg) significantly decreased the duration of 
immobility (p < 0.01) in a dose-dependent 
manner, when compared with the control group. 
The imipramine at 15 mg/kg, also significantly 
reduced immobility duration relative to control. 
 
Effect of curculigoside on depressive-like 
mice  
 
The effects of curculigoside on immobility time 
were also determined in TST in mice. As shown 
in Fig. 3, imipramine (15 mg/kg), significantly 
decreased duration of immobility (p < 0.01) when 
compared to the vehicle-treated control group. 
Interestingly, curculigoside (10, 20 and 40 mg/kg) 
also produced significant reduction in immobility 
time (p < 0.05, p < 0.01, p < 0.01, respectively), 
in a dose-dependent manner. 
 
Effect of curculigoside on locomotor activity 
 
As can be seen from Fig. 4, imipramine (15 
mg/kg) significantly increased locomotor activity 
when compared with the vehicle-treated control 
group (p < 0.01). However, treatment with 
curculigoside at all the tested doses did not affect 
mobility performance. 
 
Table 1: 1H NMR (600 Hz) and 13 C NMR (150 Hz) data of curculigoside in DMSO-d6 (δ, ppm) 
 
No. δH(J)       δ C No. δH(J) δ C 
1  128.1 5’ 6.77 (1H, d, J = 8.1), 112.9 
2  148.2 6’  157.1 
3 6.95 (1H, d, J = 8.7) 118.0 7’  167.3 
4 6.55 (1H, dd, J = 3.2, 8.9) 115.9 1’’ 4.68 (1H, d, J = 7.7) 104.1 
5  151.9 2’’  74.2 
6 6.80 (1H, d, J = 3.2) 115.3 3’’  78.1 
7 5.35 (2H, s) 62.4 4’’  69.7 
1’  105.3 5’’  76.1 
2’  157.2 6’’  61.3 
3’ 6.79 (1H, d, J = 8.1), 115.0 5-OH 9.12 (1H, s)  





























Figure 1: Structure of curculigoside 
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Figure 2: Effect of the curculigoside on immobility time in FST experiment. Imipramine (15 mg/kg) was used as 
reference drug. Data are presented as mean ± SD (n = 10). The asterisks indicate significant differences from the 
control, *p < 0.05, **p < 0.01 
 
 
Figure 3: Effect of the curculigoside on immobility time in TST. Imipramine (15 mg/kg) was used as standard 
drug. Data are presented as mean ± SD (n = 10). The asterisks indicate significant differences from the control, 
*p < 0.05, **p < 0.01 
 
 
Figure 4: Effect of the curculigoside on spontaneous behavior in the OFT experiment. Imipramine (15 mg/kg) 
was used as reference drug. Data are presented as mean ± SD (n = 10). The asterisks indicate significant 
differences from the control, **p < 0.01. 
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Effect of curculigoside on levels of DA, NE, 
and 5-HT in CMS rats 
 
The effect of curculigoside on the levels of DA, 
NE, and 5-HT in CMS rats are shown in Fig. 5. 
The reference drug imipramine (15 mg/kg) 
significantly increased levels of DA, NE, and 5-
HT in CMS rats (p < 0.05, p < 0.01, and p < 0.01, 
respectively), when compared with the vehicle-
treated control group. Similarly, curculigoside, at 
doses of 10, 20, 40 mg/kg, also resulted in 
increased levels of DA in the hippocampus of 
CMS rats (p < 0.01). After treatment with 
different concentrations of curculigoside, the 
levels of NE and 5-HT were also significantly 
increased in a dose-dependent manner (p < 
0.05, p < 0.01, and p < 0.01, respectively). 
 
Effect of curculigoside on the expression of 
BDNF in CMS rats  
 
In Fig. 6, it can be observed that curculigoside, at 
doses of 10, 20, 40mg/kg, significantly up-
regulated protein expression levels of BDNF in 
the hippocampus of CMS rats (p < 0.01), in a 
dose-dependent manner, when compared with 
the control group. 
 
 
Figure 5: Effect of curculigoside on DA (A), NE (B), and 5-HT (C) levels in the hippocampus of CMS rats. 
Imipramine (15 mg/kg) was used as reference drug. Data are represented as mean ± SD (n = 10). The asterisks 
indicate significant differences from the control, *p< 0.05, **p < 0.01 
 
 
Figure 6: Effect of the curculigoside on BDNF expression in brain. Data are represented as mean ± SD (n = 4). 
The asterisks indicate significant differences from the control, **p <0.01 
Wang et al 




In this study, an animal behaviour model for FST, 
TST and OFT was used to investigate the 
antidepressant-like activity of curculigoside. FST 
and TST are preliminary and simple‘‘behavior 
despair” models which are widely used to screen 
for anti-depressant drugs [14,15]. The behavior 
despair test is centered on a rodent's response 
to the threat of drowning, and its result has been 
used to determine susceptibility to negative 
mood. 
 
The results of the present study show that in the 
FST and TST on mice, treatment with 
curculigoside significantly decreased immobility 
time in a dose-dependent manner, which 
indicates that curculigoside has antidepressant 
activity in the ‘‘behavior despair’’ test. OFT is 
used to assess general locomotor activity levels 
and anxiety in rodents. Curculigoside did not 
significantly affect locomotor activity of mice in 
the open-field test, which shows that the 
treatments given had no effect on mobility 
performance, and further demonstrates that 
curculigoside has antidepressant activity in mice. 
Elevations in the brain levels of DA, NE, and 5-
HT in the brain have been reported to be 
effective in the treatment of depression [16]. DA, 
NE, and 5-HT are neurotransmitters and neuro-
modulators. Many anti-depressant drugs elevate 
these neurotransmitters. In the present 
investigation, treatment with curculigoside 
significantly enhanced the levels of DA, NE, and 
5-HT in the hippocampus of CMS rats, which 
indicates that the antidepressant activity of 
curculigoside relates to increases in levels of 
neurotransmitters. 
 
BDNF is a secretory protein of the neurotrophin 
family which has been reported to be implicated 
in depression [17]. A previous study has reported 
that knock-out of BDNF in the dentate gyrus 
produced a depression-like response [18]. In 
addition, it has been reported that depressed 
patients often manifest decreased serum BDNF 
levels [19]. In the present study, treatment with 
curculigoside up-regulated expression levels of 
BDNF in the hippocampus of CMS rats, which 
suggests that the antidepressant-like effect of 





This study demonstrates that curculigoside 
possesses significant antidepressant-like activity, 
which mechanisms most likely involve increases 
in the levels of DA, NE, 5-HT as well as 
enhanced expression of BDNF. Thus, 
curculigoside has a potential as a new drug 
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